Plus Therapeutics Inc
NASDAQ:PSTV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (40.2), the stock would be worth $37.16 (478% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 7 | $6.43 |
0%
|
| 3-Year Average | 40.2 | $37.16 |
+478%
|
| 5-Year Average | 53 | $48.98 |
+662%
|
| Industry Average | 6.2 | $5.75 |
-11%
|
| Country Average | 3 | $2.81 |
-56%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
$42.1m
|
/ |
Jan 2026
$5.2m
|
= |
|
|
$42.1m
|
/ |
Dec 2026
$5.9m
|
= |
|
|
$42.1m
|
/ |
Dec 2027
$21.3m
|
= |
|
|
$42.1m
|
/ |
Dec 2028
$48.7m
|
= |
|
|
$42.1m
|
/ |
Dec 2029
$136.5m
|
= |
|
|
$42.1m
|
/ |
Dec 2030
$189.8m
|
= |
|
|
$42.1m
|
/ |
Dec 2031
$341.6m
|
= |
|
|
$42.1m
|
/ |
Dec 2032
$642.9m
|
= |
|
|
$42.1m
|
/ |
Dec 2033
$948.3m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Plus Therapeutics Inc
NASDAQ:PSTV
|
45.3m USD | 7 | -2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 691 034.4 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | 6.6 | 83.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 6.1 | 23.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 5.8 | 18.7 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 092.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 8.4 | 27.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 4 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 10.7 | 37.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 19.6 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 3.5 | 31.1 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 3 |
| 70th Percentile | 5.3 |
| Max | 4 613 320.1 |
Other Multiples
Plus Therapeutics Inc
Glance View
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The company is headquartered in Austin, Texas and currently employs 14 full-time employees. The company went IPO on 2000-08-09. The firm is focused on developing treatments for patients battling cancer. The firm provides nanotechnology platform to reformulate and improve workhorse chemotherapeutics to provide benefits to patients and healthcare providers. The firm is focused on developing generic oncology drugs that address unmet medical and market needs. The Company’s lead product candidate, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel. DocePLUS is developed for the treatment of patients with small cell lung cancer (SCLC). The firm is also developing DoxoPLUS, which is a generic PEGylated liposomal formulation of doxorubicin. DoxoPLUS is developed for the treatment of breast cancer, ovarian cancer, multiple myeloma and Kaposi’s sarcoma. The firm also focuses on developing Rhenium-186 NanoLiposome (186RNL) for the treatment of recurrent glioblastoma-a rare, incurable and fatal disease.
